摘要
目的探讨重组人血小板生成素联合利妥昔单抗治疗血小板减少症的临床效果及对患者免疫功能的影响。方法126例糖皮质激素耐药的成人原发性免疫性血小板减少症患者随机分为两组,对照组采用利妥昔单抗治疗,观察组采用重组人血小板生成素联合利妥昔单抗治疗,比较两组的治疗效果、免疫功能指标及不良反应。结果观察组的治疗总有效率为93.65%,高于对照组的71.43%(P<0.05)。治疗后,观察组的CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)水平均高于对照组,CD8^(+)水平低于对照组(P<0.05)。两组的不良反应总发生率比较,差异无统计学意义(P>0.05)。结论重组人血小板生成素与利妥昔单抗联合治疗血小板减少症的效果显著,可有效改善患者的免疫功能,且安全性较高。
Objective To explore the clinical effect of recombinant human thrombopoietin combined with rituximab in the treatment of thrombocytopenia and its impact on patients’immune function.Methods 126 adult patients with glucocorticoid-resistant primary immune thrombocytopenia were randomly divided into two groups.The control group was treated with rituximab,and the observation group was treated with recombinant human thrombopoietin combined with rituximab.The therapeutic effect,immune function indicators and adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was 93.65%,higher than 71.43% in the control group(P<0.05).After treatment,the levels of CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)in the observation group were higher than those in the control group,and the level of CD8^(+)was lower than that in the control group(P<0.05).No significant difference showed in the total incidence of adverse reactions between the two groups(P>0.05).Conclusions Recombinant human thrombopoietin combined with rituximab in the treatment of thrombocytopenia has significant effect and high safety,and can effectively improve patients’immune function.
作者
武玉慧
徐征
WU Yuhui;XU Zheng(Department of Hematology,Xinyang Central Hospital,Xinyang 464000,China)
出处
《临床医学工程》
2022年第12期1679-1680,共2页
Clinical Medicine & Engineering
